<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04147130</url>
  </required_header>
  <id_info>
    <org_study_id>PI 18/01303,18/01515,18/01812</org_study_id>
    <nct_id>NCT04147130</nct_id>
  </id_info>
  <brief_title>MultiPAP Plus: Improving Prescription in Primary Care Patients With Multimorbidity and Polypharmacy</brief_title>
  <acronym>MultiPAP Plus</acronym>
  <official_title>Efectiveness of the MultiPAP Plus Intervention in Young-old Patients With Multimorbidity and Polypharmacy Aimed at Improving Prescription in Primary Care: Cluster RCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Aragones de Ciencias de la Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gerencia de Atención Primaria, Madrid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aragon Institute for Health Research (IIS Aragón)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Andaluz Health Service</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundación de Investigación e Innovación Biomédica Atención Primaria (FIIBAP)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Red de Investigación en Servicios de Salud y Enfermedades Crónicas (REDISSEC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Aragones de Ciencias de la Salud</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assesses the effectiveness of a complex intervention in young-old patients with
      multimorbidity and polypharmacy aimed at improving physician drug prescription in primary
      care, measured by hospitalization-mortality at six 6 (T1), 12 (T2) and 18 (T3) months from
      baseline compared to usual care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design: Pragmatic cluster randomized clinical trial with 18 months follow-up.

      Unit of randomization: general practitioner.

      Unit of analysis: patient.

      Setting: Primary Health Care Centres in three different Spanish Autonomous Communities
      (Aragón, Madrid and Andalucía).

      Population: Patients 65-74 years of age with multimorbidity (3 or more chronic diseases) and
      polypharmacy (5 or more drugs taken for at least three months). N=1234 patients (617 in each
      arm, 8 patients per physician) will be recruited by general practitioners before
      randomization.

      Intervention: Complex intervention incorporating previous MultiPAP intervention (based on the
      ARIADNE principles with two main components: 1) Training of general practitioners and 2)
      Patient-centered clinical interview) And it adds a clinical-decision support system to help
      structured treatment-plan review.

      Control group: usual care.

      Variables: First level (Patient): a) Main: hospitalizations and/or mortality; b) Secondary:
      health services use, quality of life (Euroqol 5D-5L), disability (WHODAS), fractures,
      pharmacotherapy and adherence to treatment (Morisky-Green), clinical and socio-demographic.
      Second level (Physician): a) Socio-demographic. b) CDSS use: acceptance and satisfaction of
      health care provider use c) Professional background: time in the position, center
      characteristics and medical education involvement.

      Analysis: All analyses will be carried out adhering to the intention-to-treat principle.
      Description of baseline characteristics. Basal comparison between groups. Analysis of primary
      outcome: difference in percentages in the final combined variable from 0 (T0) to 18 months
      (T3), with its corresponding 95% CI. Adjustement by main confounding and prognostic factors
      will be performed through a multilevel analysis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 18, 2020</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospitalizations and/or mortality</measure>
    <time_frame>From Baseline to Month 18</time_frame>
    <description>Difference in percentages in the final combined variable</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations and/or mortality (T2)</measure>
    <time_frame>From Baseline to Month 12</time_frame>
    <description>Difference in percentages in the final combined variable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic adherence questionnaire</measure>
    <time_frame>Baseline, 6, 12 and 18 months</time_frame>
    <description>Morisky-Green questionnaire. Dicotomous variable. Any wrong answer to any of the four questions would mean worse adherence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Safety: Potentially Drug-Drug interactions (DDI), Potentially Innappropiate Medication (PIM), Adverse Drug Reactions</measure>
    <time_frame>Baseline, 6, 12 and 18 months</time_frame>
    <description>Number of Potentially Drug-Drug interactions (DDI) per patient, Number of Potentially Innappropiate Medication (PIM) per patient, Number of Adverse Drug Reactions per patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of health services</measure>
    <time_frame>at 12 and at 18 months</time_frame>
    <description>Number of Unscheduled and/or avoidable hospitalizations, number of visits to emergency services and primary care (Family Physician and nurse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability</measure>
    <time_frame>Baseline, 12 and 18 months</time_frame>
    <description>World Health Organization Disabilty Assessment (WHODAS). 12-items abbreviated scale (0=No Difficulty, 1=Mild Difficulty, 2=Moderate Difficulty, 3=Severe Difficulty, and 4=Extreme Difficulty or Cannot Do). Maximum 48 points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived Quality of Life: Euroqol 5D-5L questionnaire</measure>
    <time_frame>Baseline, 12 and 18 months</time_frame>
    <description>EQ5D is one of the most widely used health states descriptive system and has a valuation in Spain.
EQ-5D questionnaires have 5 dimensions: &quot;Mobility&quot;, &quot;Human Autonomy,&quot; &quot;Current Activities&quot;, &quot;Pain / Discomfort&quot;, &quot;Anxiety / Depression&quot; and all dimensions are described by 5 problem levels corresponding to patient response choices.
A quality of life score is obtained according to the answers to the questionnaires.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>System Usability Scale of the CDSS</measure>
    <time_frame>at 6 and 18 months.</time_frame>
    <description>It consists of a 10 item questionnaire with five response options for respondents; from Strongly agree to Strongly disagree</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1234</enrollment>
  <condition>Multimorbidity</condition>
  <condition>Polypharmacy</condition>
  <condition>Comorbidities and Coexisting Conditions</condition>
  <condition>Clinical Decision-Support Systems</condition>
  <arm_group>
    <arm_group_label>MultiPAP Plus intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Complex intervention with general practitioners and patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will recieve the usual clinical care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MultiPAP Plus</intervention_name>
    <description>Complex intervention incorporating previous MultiPAP intervention (based on the ARIADNE principles with two main components: 1) Training of general practitioners and 2) Patient-centered clinical interview) And it adds a clinical-decision support system to help structured treatment-plan review.</description>
    <arm_group_label>MultiPAP Plus intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual care</intervention_name>
    <description>Patients will receive the usual clinical care based on current clinical practice guidelines.</description>
    <arm_group_label>MultiPAP Plus intervention</arm_group_label>
    <arm_group_label>Usual care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 65-74 years of age with multimorbidity (3 or more chronic diseases) and
             polypharmacy (5 or more drugs taken for at least three months).

          -  Informed consent.

        Exclusion Criteria:

          -  Institutionalized patient at nursing homes or similar

          -  Life expectancy &lt; 12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra Prados-Torres, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Aragonés de Ciencias de la Salud (IACS)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Prados-Torres, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Servicio Andaluz de Salud (Andaluz Health Service)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabel Del Cura-González, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gerencia Asistencial de Atención Primaria, Madrid</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandra Prados-Torres, MD, PhD</last_name>
    <phone>+34 976 76 5500</phone>
    <phone_ext>5370</phone_ext>
    <email>sprados.iacs@aragon.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juan A Lopez-Rodriguez, MD, PhD</last_name>
    <phone>+34913700697</phone>
    <phone_ext>300717</phone_ext>
    <email>juanantonio.lopez@salud.madrid.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Servicio Andaluz de Salud</name>
      <address>
        <city>Málaga</city>
        <state>Andalucía</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Prados-Torres, MD, PhD</last_name>
      <phone>+34 951 290 310</phone>
      <email>juand.prados.sspa@juntadeandalucia.es</email>
    </contact>
    <investigator>
      <last_name>Francisca Leiva-Fernández, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessandra Marengoni, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fernando López-Verde, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Josefa Bujalance-Zafra, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>José M Ruiz-San-Basilio, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nuria García-Aguas-Soler, Pharm, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>María I Márquez-Chamizo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>María P Barnestein-Fonseca, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rubén Vázquez Alarcón, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miguel Domínguez Santaella, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Inmaculada Moraga Ropero, Pharmacist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Jiménez Rios, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Aragonés de Ciencias de la Salud (IACS)</name>
      <address>
        <city>Zaragoza</city>
        <state>Aragón</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Prados-Torres, MD, PhD</last_name>
      <phone>+34976765500</phone>
      <phone_ext>5370</phone_ext>
      <email>sprados.iacs@aragon.es</email>
    </contact>
    <investigator>
      <last_name>Amaia Calderón-Larrañaga, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Beatriz Poblador-Plou, Statistician, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Gimeno-Miguel, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Victoria Pico-Soler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Javier Marta-Moreno, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mercedes Aza-Pascual-Salcedo, Pharma, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mercedes Clerencia-Sierra, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos Coscollar-Santaliestra, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christiane Muth, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Poncel-Falcó, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisca González-Rubio, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis A Gimeno-Feliu, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mónica Machón Sobrado, Biologist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jesús Diez Manglano, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Cristina Bandrés Liso, Pharmacist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aida Moreno Juste, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Inmaculada Guerrero Fernández de Alba, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>María Bestué Cardiel, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gerencia Asistencial de Atención Primaria de Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Del Cura-González, MD, PhD</last_name>
      <phone>+34913700697</phone>
      <email>isabel.cura@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Teresa Sanz-Cuesta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ricardo Rodriguez-Barrientos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mercedes Rumayor-Zarzuelo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eugenia Tello-Bernabé, Nurse</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena Polentinos-Castro, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ángel Mataix-SanJuan, Pharmacist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marta Alcaraz-Borrajo, Pharmacist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Virginia Hernández-Santiago, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gloria Ariza-Cardiel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis Sánchez-Perruca, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisca García-De-Blas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eloisa Rogero-Blanco, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mar Álvarez-Villalba, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amaya Azcoaga-Lorenzo, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana I González-González, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jesús Martín-Fernández, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>José M Valderas-Martínez, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mariel Morey-Montalvo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan A López-Rodríguez, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan C Gil-Moreno, Statistician</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 22, 2019</study_first_submitted>
  <study_first_submitted_qc>October 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2019</study_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Aragones de Ciencias de la Salud</investigator_affiliation>
    <investigator_full_name>Alexandra Prados Torres</investigator_full_name>
    <investigator_title>Principal Investigator, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Primary Health Care</keyword>
  <keyword>Medication Adherence</keyword>
  <keyword>Disability</keyword>
  <keyword>Patient-Centered Care</keyword>
  <keyword>Ariadne Principles</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

